Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Medullary thyroid cancer (MTC) is associated with activation of mammalian target of rapamycin (mTOR) signaling pathways. Recent studies showed that the antidiabetic agent metformin decreases proliferation of cancer cells through 5′-AMP-activated protein kinase (AMPK)-dependent inhibition of mTOR. In the current study, we assessed the effect of metformin on MTC cells. For this purpose, we determined growth, viability, migration, and resistance to anoikis assays using two MTC-derived cell lines (TT and MZ-CRC-1). Expressions of molecular targets of metformin were examined in MTC cell lines and in 14 human MTC tissue samples. We found that metformin inhibited growth and decreased expression of cyclin D1 in MTC cells. Treatment with metformin was associated with inhibition of mTOR/p70S6K/pS6 signaling and downregulation of pERK in both TT and MZ-CRC-1 cells. Metformin had no significant effects on pAKT in the cell lines examined. Metformin-inducible AMPK activation was noted only in TT cells. Treatment with AMPK inhibitor (compound C) or AMPK silencing did not prevent growth inhibitory effects of metformin in TT cells. Metformin had no effect on MTC cell migration but reduced the ability of cells to form multicellular spheroids in nonadherent conditions. Immunostaining of human MTC showed over-expression of cyclin D1 in all tumors compared with corresponding normal tissue. Activation of mTOR/p70S6K was detected in 8/14 (57.1%) examined tumors. Together, these findings indicate that growth inhibitory effects in MTC cells are associated with downregulation of both mTOR/6SK and pERK signaling pathways. Expression of metformin's molecular targets in human MTC cells suggests its potential utility for the treatment of MTC in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“In addition to being directly phosphorylated by AKT, TSC2 can be phosphorylated and inactivated by ERK as well as its downstream kinase RSK (Shaw & Cantley 2006).”
BackgroundEl-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“On the intracellular level, metformin inhibits mitochondrial complex I, which leads to an altered AMP/ATP ratio and activation of AMPK (El-Mir et al. 2000).”
BackgroundDowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 7×
“(doi:10.1038/ sj.onc.1211024)18212742 Ben Sahra I , Le Marchand-Brustel Y , Tanti JF & Bost F 2010 Metformin in cancer therapy: a new perspective for an old antidiabetic drug?”
BackgroundResultInfluentialLKB1 and AMP-activated protein kinase control of mTOR signalling and growth
Shaw, R. J. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01972.x · Cited by 644 · cited 2×
“AMPK directly phosphor-ylates the TSC2 tumor suppressor on conserved serine sites distinct from those targeted by other kinases, leading to the inhibition of mTORC1 (Shaw 2009, Luo et al. 2010).”
BackgroundMetformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 7×
“(doi:10.1038/ sj.onc.1211024)18212742 Ben Sahra I , Le Marchand-Brustel Y , Tanti JF & Bost F 2010 Metformin in cancer therapy: a new perspective for an old antidiabetic drug?”
BackgroundInfluentialChen, G., Xu, S., Renko, K., & Derwahl, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1754 · Cited by 196
Cited by
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
Curry, J. M., Sprandio, J., Cognetti, D., Luginbuhl, A., Bar-ad, V., Pribitkin, E., & Tuluc, M. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.03.003 · Cited by 293
The relationship between type 2 diabetes mellitus and related thyroid diseases
Wang, C. (2013) · Journal of Diabetes Research · doi:10.1155/2013/390534 · Cited by 273
Metformin Targets Multiple Signaling Pathways in Cancer
Lei, Y., Yi, Y., Liu, Y., Liu, X., Keller, E. T., Qian, C.-N., Zhang, J., & Lu, Y. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0184-9 · Cited by 152
Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses
Li, H., Chen, Y., Hu, L., Yang, W., Gao, Z., Liu, M., Tao, H., & Li, J. (2023) · European Journal of Medical Research · doi:10.1186/s40001-023-01287-0 · Cited by 10
“Metformin treatment was associated with inhibition of mTOR/p6S6K/pS1 signaling and downregulation of pERK in MTC-derived TT and MZ-CRC-70 cell lines [75].”
Background
Metadata
- Authors
- Klubo-Gwiezdzinska, J., Jensen, K., Costello, J., Patel, A., Hoperia, V., Bauer, A., Burman, K. D., Wartofsky, L., & Vasko, V.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2012-03-02
- Volume
- 19
- Issue
- 3
- Pages
- 447-456
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2102192525
- Cited by
- 87
- References
- 8
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. https://app.cochat.ai/papers/10.1530/erc-12-0046
- The paper
- Klubo-Gwiezdzinska, J., Jensen, K., Costello, J., Patel, A., Hoperia, V., Bauer, A., Burman, K. D., Wartofsky, L., & Vasko, V. (2012). Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocrine-Related Cancer. https://doi.org/10.1530/erc-12-0046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.